213
Views
11
CrossRef citations to date
0
Altmetric
Original Research

Risk Factors for and Clinical Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Nosocomial Infections: A Retrospective Study in a Tertiary Hospital in Beijing, China

ORCID Icon, , , ORCID Icon, , ORCID Icon, & show all
Pages 1393-1401 | Published online: 13 Apr 2021

References

  • Perez F, Van Duin D. Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patients. Cleve Clin J Med. 2013;80(4):225–233. doi:10.3949/ccjm.80a.1218223547093
  • Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281. doi:10.1111/j.1469-0691.2011.03570.x21793988
  • MacKenzie FM, Forbes KJ, Dorai-John T, Amyes SGB, Gould IM. Emergence of a carbapenem-resistant Klebsiella pneumoniae. Lancet. 1997;350(9080):783. doi:10.1016/s0140-6736(05)62567-69298003
  • Han R, Shi Q, Wu S, et al. Dissemination of carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) among carbapenem-resistant enterobacteriaceae isolated from adult and children patients in China. Front Cell Infect Microbiol. 2020;10:314. doi:10.3389/fcimb.2020.0031432719751
  • Baran I, Aksu N. Phenotypic and genotypic characteristics of carbapenem-resistant Enterobacteriaceae in a tertiary-level reference hospital in Turkey. Ann Clin Microbiol Antimicrob. 2016;15(1):20. doi:10.1186/s12941-016-0136-227048322
  • Jamal AJ, Garcia-Jeldes F, Baqi M, et al. Infection prevention and control practices related to carbapenemase-producing Enterobacteriaceae (CPE) in acute-care hospitals in Ontario, Canada. Infect Control Hosp Epidemiol. 2019;40(9):1006–1012. doi:10.1017/ice.2019.17331244458
  • Tran DM, Larsson M, Olson L, et al. High prevalence of colonisation with carbapenem-resistant Enterobacteriaceae among patients admitted to Vietnamese hospitals: risk factors and burden of disease. J Infect. 2019;79(2):115–122. doi:10.1016/j.jinf.2019.05.01331125639
  • Perovic O, Ismail H, Quan V, et al. Carbapenem-resistant Enterobacteriaceae in patients with bacteraemia at tertiary hospitals in South Africa, 2015 to 2018. Eur J Clin Microbiol Infect Dis. 2020;39(7):1287–1294. doi:10.1007/s10096-020-03845-432124106
  • David S, Reuter S, Harris SR, et al. Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread. Nat Microbiol. 2019;4(11):1919–1929. doi:10.1038/s41564-019-0492-831358985
  • Wang Q, Zhang Y, Yao X, et al. Risk factors and clinical outcomes for carbapenem-resistant Enterobacteriaceae nosocomial infections. Eur J Clin Microb Infect Dis. 2016;35(10):1679–1689. doi:10.1007/s10096-016-2710-0
  • Liu J, Wang H, Huang Z, et al. Risk factors and outcomes for carbapenem-resistant Klebsiella pneumoniae bacteremia in onco-hematological patients. J Infect Dev Ctries. 2019;13(5):357–364. doi:10.3855/jidc.1118932053504
  • Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev. 2018;31(2). doi:10.1128/cmr.00079-17
  • Wang Z, Qin RR, Huang L, Sun LY. Risk factors for carbapenem-resistant klebsiella pneumoniae infection and mortality of klebsiella pneumoniae infection. Chin Med J. 2018;131(001):56. doi:10.4103/0366-6999.22126729271381
  • CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 28th. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2018
  • Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–332. doi:10.1016/j.ajic.2008.03.00218538699
  • Kofteridis DP, Valachis A, Dimopoulou D, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonization: a case-case-control study. J Infect Chemother. 2014;20(5):293–297. doi:10.1016/j.jiac.2013.11.00724703709
  • Jiao Y, Qin Y, Liu J, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonization and predictors of mortality: a retrospective study. Pathog Glob Health. 2015;109(2):68–74. doi:10.1179/2047773215Y.000000000425707874
  • Vardakas KZ, Matthaiou DK, Falagas ME, Antypa E, Koteli A, Antoniadou E. Characteristics, risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in the intensive care unit. J Infect. 2015;70(6):592–599. doi:10.1016/j.jinf.2014.11.00325447713
  • In’t Holt Voor AF, Vos MC. A systematic review and meta-analyses of the clinical epidemiology of carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2018;62(1). doi:10.1128/aac.01730-17
  • Qin X, Wu S, Hao M, et al. The colonization of carbapenem-resistant Klebsiella pneumoniae: epidemiology, resistance mechanisms, and risk factors in patients admitted to intensive care units in China. J Infect Dis. 2020;221(Supplement_2):S206–S214. doi:10.1093/infdis/jiz62232176790
  • Xiao T, Zhu Y, Zhang S, et al. A retrospective analysis of risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae bacteremia in nontransplant patients. J Infect Dis. 2020;221(Supplement_2):S174–S183. doi:10.1093/infdis/jiz55932176799
  • Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother. 2008;52(3):1028–1033. doi:10.1128/AAC.01020-0718086836
  • Ahn JY, Song JE, Kim MH, et al. Risk factors for the acquisition of carbapenem-resistant Escherichia coli at a tertiary care center in South Korea: a matched case-control study. Am J Infect Control. 2014;42(6):621–625. doi:10.1016/j.ajic.2014.02.02424837112
  • Gómez Rueda V, Zuleta Tobón JJ. Risk factors for infection with carbapenem-resistant Klebsiella pneumoniae: a case-case-control study. Colomb Med. 2014;45(2):54–60. doi:10.25100/cm.v45i2.1417
  • Tanimoto K, Tomita H, Fujimoto S, Okuzumi K, Ike Y. Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. Antimicrob Agents Chemother. 2008;52(10):3795–3800. doi:10.1128/AAC.00464-0818694945
  • Kaye KS, Pogue JM. Infections caused by resistant gram-negative bacteria: epidemiology and management. Pharmacotherapy. 2015;35(10):949–962. doi:10.1002/phar.163626497481
  • Salomao MC, Guimaraes T, Duailibi DF, et al. Carbapenem-resistant Enterobacteriaceae in patients admitted to the emergency department: prevalence, risk factors, and acquisition rate. J Hosp Infect. 2017;97(3):241–246. doi:10.1016/j.jhin.2017.08.01228826688
  • Akgul F, Bozkurt I, Sunbul M, Esen S, Leblebicioglu H. Risk factors and mortality in the carbapenem-resistant Klebsiella pneumoniae infection: case control study. Pathog Glob Health. 2016;110(7–8):321–325. doi:10.1080/20477724.2016.125497627903130
  • Li JH, Li YY, Song N, Chen Y. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection: a meta-analysis. J Glob Antimicrob Resist. 2020;21:306–313. doi:10.1016/j.jgar.2019.09.00631525540
  • Tischendorf J, de Avila RA, Safdar N. Risk of infection following colonization with carbapenem-resistant Enterobactericeae: a systematic review. Am J Infect Control. 2016;44(5):539–543. doi:10.1016/j.ajic.2015.12.00526899297
  • Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect. 2011;17(12):1798–1803. doi:10.1111/j.1469-0691.2011.03514.x21595793
  • Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017;16(1):18. doi:10.1186/s12941-017-0191-328356109
  • Vardakas KZ, Rafailidis PI, Konstantelias AA, Falagas ME. Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study, the patient, the bug or the drug? J Infect. 2013;66(5):401–414. doi:10.1016/j.jinf.2012.10.02823142195
  • Trong Le N, Viet HD, Quoc Doan T, et al. In vitro antimicrobial activity of essential oil extracted from leaves of Leoheo domatiophorus Chaowasku, D.T. Ngo and H.T. Le in Vietnam. Plants. 2020;9(4):453. doi:10.3390/plants9040453
  • Le NT, Donadu MG, Ho DV, et al. Biological activities of essential oil extracted from leaves of Atalantia sessiflora Guillauminin Vietnam. J Infect Dev Ctries. 2020;14(9):1054–1064. doi:10.3855/jidc.1246933031096
  • Donadu MG, Trong Le N, Viet Ho D, et al. Phytochemical compositions and biological activities of essential oils from the leaves, rhizomes and whole plant of Hornstedtia bella Skornick. Antibiotics. 2020;9(6):334. doi:10.3390/antibiotics9060334
  • Mohamed SH, Mohamed MSM, Khalil MS, Azmy M, Mabrouk MI. Combination of essential oil and ciprofloxacin to inhibit/eradicate biofilms in multidrug-resistant Klebsiella pneumoniae. J Appl Microbiol. 2018;125(1):84–95. doi:10.1111/jam.1375529517825